Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Spinosad: adverse event reports

All products with this active ingredient · 1 FDA-approved application in the Green Book

72,825reports naming this ingredient, 2007–20265.4% of all reports · about 3,850 a year
82reports, 12 months to March 202697 in the 12 months before
11%classed serious, as reportedof 48,187 reports stating it
2.6%record death or euthanasia, as reported1,886 reports
78.4%of reports concern dogs5.8% of all dog reports

FDA has received 72,825 adverse event reports in which a drug is recorded with spinosad as its active ingredient, from May 2007 to March 2026. The Green Book lists 1 FDA-approved application with this single active ingredient.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 82 reports named it, down 15% from 97 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 3,850 reports a year and 5.4% of all 1,357,245 reports (5.8% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

Reporters most often listed vomiting (27.2%), emesis (25.7%) and lack of efficacy (ectoparasite) - flea (19.3%). A report can list several signs, so shares add to more than 100%; 1,661 different terms appear across these reports. Vomiting appears in 27.2% of these reports, about the same share as in the pooled reports for every drug containing spinosad (24.3%).

78.4% of reports concern dogs. Not every report describes illness: 13.8% were filed wholly or partly as lack of expected effectiveness and 9.7% as product or packaging defects. Of reports that state seriousness, 11% were classed as serious, and 2.6% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog531 · peak 27
Apr 2021: 23May 2021: 18Jun 2021: 11Jul 2021: 27Aug 2021: 19Sep 2021: 22Oct 2021: 13Nov 2021: 7Dec 2021: 7Jan 2022: 14Feb 2022: 20Mar 2022: 19Apr 2022: 15May 2022: 23Jun 2022: 11Jul 2022: 14Aug 2022: 13Sep 2022: 16Oct 2022: 14Nov 2022: 9Dec 2022: 10Jan 2023: 8Feb 2023: 4Mar 2023: 7Apr 2023: 12May 2023: 17Jun 2023: 5Jul 2023: 9Aug 2023: 12Sep 2023: 6Oct 2023: 7Nov 2023: 4Dec 2023: 3Jan 2024: 2Feb 2024: 2Apr 2024: 2May 2024: 9Jun 2024: 4Jul 2024: 3Aug 2024: 4Sep 2024: 5Oct 2024: 9Nov 2024: 3Dec 2024: 3Jan 2025: 1Feb 2025: 7Mar 2025: 3Apr 2025: 1May 2025: 15Jun 2025: 5Jul 2025: 6Aug 2025: 5Sep 2025: 1Oct 2025: 6Nov 2025: 4Dec 2025: 2Jan 2026: 5Feb 2026: 3Mar 2026: 22022202320242025
Cat350 · peak 28
Apr 2021: 22May 2021: 18Jun 2021: 25Jul 2021: 19Aug 2021: 28Sep 2021: 14Oct 2021: 17Nov 2021: 6Dec 2021: 4Jan 2022: 7Feb 2022: 5Mar 2022: 8Apr 2022: 2May 2022: 8Jun 2022: 8Jul 2022: 7Aug 2022: 10Sep 2022: 8Oct 2022: 9Nov 2022: 7Dec 2022: 2Jan 2023: 1Feb 2023: 8Mar 2023: 1Apr 2023: 7May 2023: 4Jun 2023: 6Jul 2023: 6Aug 2023: 4Sep 2023: 2Oct 2023: 2Nov 2023: 5Dec 2023: 5Jan 2024: 4Feb 2024: 1Mar 2024: 2Apr 2024: 1May 2024: 6Jul 2024: 3Aug 2024: 3Sep 2024: 2Oct 2024: 8Nov 2024: 1Dec 2024: 4Jan 2025: 1Feb 2025: 7Mar 2025: 2May 2025: 6Jun 2025: 2Jul 2025: 1Aug 2025: 3Oct 2025: 3Nov 2025: 1Jan 2026: 3Feb 2026: 12022202320242025
Horse0 · peak 1
2022202320242025
Other82 · peak 7
Apr 2021: 6May 2021: 5Jun 2021: 7Jul 2021: 6Aug 2021: 6Sep 2021: 3Oct 2021: 1Nov 2021: 1Dec 2021: 2Jan 2022: 2Feb 2022: 3Mar 2022: 2Apr 2022: 3May 2022: 1Jun 2022: 3Sep 2022: 2Oct 2022: 3Nov 2022: 1Jan 2023: 1Feb 2023: 1Mar 2023: 1Jun 2023: 2Jul 2023: 1Sep 2023: 2Oct 2023: 1Dec 2023: 2Mar 2024: 1Apr 2024: 1May 2024: 1Jun 2024: 1Jul 2024: 2Aug 2024: 1Apr 2025: 1Jun 2025: 2Jul 2025: 1Dec 2025: 2Feb 2026: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

05,31810,6362007: 5620072008: 3,3452009: 3,60120092010: 9,0002011: 9,76620112012: 10,1362013: 10,63620132014: 7,5642015: 6,35820152016: 4,5892017: 2,95820172018: 1,7442019: 1,22020192020: 7912021: 43520212022: 2792023: 15620232024: 882025: 8820252026: 15

2026 covers reports received through March 2026 only.

Signs listed in reports

share of spinosad reports listing the termall drugs containing spinosadall dog reports

  1. Vomiting27.2%19,843
  2. Emesis[vomiting]25.7%18,728
  3. Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]19.3%14,080
  4. Lethargy[unusually tired or inactive]7.1%5,172
  5. Unpalatable[legacy FDA term: the animal would not take it]7%5,099
  6. Depression[dull, quiet or withdrawn]4.4%3,228
  7. Lack of efficacy - NOS[the product did not have the expected effect]3.6%2,612
  8. Diarrhoea[diarrhea]3.3%2,434
  9. Anorexia[not eating]2.9%2,109
  10. Pruritus[itching]2.9%2,104
  11. Accidental exposure[exposure that was not intended]2.1%1,526
  12. Ataxia[unsteady, uncoordinated movement]2.1%1,515
  13. Behavioural disorder NOS[behaviour change, type not specified]1.8%1,341
  14. Seizure NOS[seizure, type not specified]1.8%1,296
  15. Trembling1.7%1,234
  16. Itching1.5%1,123
  17. Death1.5%1,098
  18. Lack of efficacy (flea)[the product did not have the expected effect: fleas]1.4%1,053
  19. Emesis (multiple)[vomiting more than once]1.3%934
  20. Convulsion[seizure]1.2%888
  21. Product problem[a product quality report, not a sign in an animal]1.2%888
  22. Shaking1.2%864
  23. Overdose[more than the labelled amount was given]1.1%837
  24. Not eating1.1%765
  25. Other abnormal test result NOS[abnormal laboratory result, type not specified]1%727
  26. Odor, Abnormal[a product quality report, not a sign in an animal]1%701
  27. Hypersalivation[drooling]0.9%690
  28. Vocalisation[crying out or unusual noise]0.9%658

Top 30 of 1,661 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal40.7%29,664
Recovered with Sequela4.4%3,174
Ongoing2.4%1,764
Died2%1,456
Euthanized0.6%432
Outcome Unknown18.6%13,542

What kind of report it was

Safety issue76.5%55,733
Lack of expected effectiveness10.1%7,378
Both safety and lack of expected effectiveness3.6%2,638
Manufacturing or product defect9.7%7,076
Other0%0

Coloured bar: reports naming spinosad. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog78.4%57,106
Cat15.9%11,576
Human exposure0.3%205
Other0%10
Other Canids0%6

Single-breed animals

Chihuahua4.3%3,150
Shih Tzu3.2%2,347
Boxer1.9%1,412
Dachshund1.8%1,341
Poodle1.7%1,268

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year9%6,541
1 to 3 years29.5%21,459
4 to 7 years24.3%17,723
8 to 11 years14.3%10,432
12 years and over7.7%5,608
Age not given15.2%11,062

Weight of the animal

Under 5 kg (11 lb)24%17,499
5 to 9.9 kg (11–22 lb)26%18,934
10 to 24.9 kg (22–55 lb)16.8%12,260
25 to 44.9 kg (55–99 lb)17.1%12,436
45 kg and over (99 lb+)1.9%1,359
Weight not given14.2%10,337

Route of administration stated in reports: oral (68,439), cutaneous (37), topical (34), other (15), respiratory (inhalation) (11), intraocular (7).

In context

MeasureSpinosadAll drugs containing spinosadAll dog reportsAll reports
Reports72,825212,330985,6751,357,245
Share of that pool's reports naming this drug—34.3%5.8%5.4%
Classed serious, of reports stating it11%11.7%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports25.9255563.8
Filed as lack of expected effectiveness (wholly or partly)13.8%——23%
Top term, share of reportsVomiting 27.2%24.3%19.7%—

The spinosad pool is every report naming spinosad alone or in any combination; this single-ingredient set accounts for 34.3% of it. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Active ingredientsReportsLatest 12 months
Milbemycin Oxime + Spinosad140,673754

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

FDA-approved products containing spinosad (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Only one approved application matches this ingredient set. FDA's records still do not say which product a report concerned: the same ingredients are also dispensed as compounded, foreign-labelled and unapproved products, and the ingredient field is completed by whoever submitted the report.

Trade nameActive ingredientsSponsorApproved forApplication
ComfortisSpinosadElanco US Inc.Dogs, CatsNADA 141-277

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about spinosad reports

How many adverse event reports has FDA received for spinosad?

72,825 reports record a drug with spinosad as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 82 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 1 approved application with this ingredient alone; the reference list on this page names them without any counts.

What signs are reported most often?

vomiting (27.2%), emesis (25.7%), lack of efficacy (ectoparasite) - flea (19.3%), lethargy (7.1%) and unpalatable (7%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (78.4%), cat (15.9%) and human exposure (0.3%). Among single-breed animals the most frequent labels are Domestic Shorthair, Chihuahua, Yorkshire Terrier and Labrador Retriever; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

82 reports in the 12 months to March 2026, down 15% from 97 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that spinosad harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of spinosad?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.